!!
#Coagulation in #Cirrhosis
https://www.gastrojournal.org/article/S0016-5085(19)35694-X/pdf
Best Practice Advice
1. Global tests of clot formation such as rotational thromboelastometry (ROTEM), thromboelastography (TEG), Sonorheometry and Thrombin generation may eventually have a role in the evaluation of clotting in patients with cirrhosis but currently lack validated target levels.
2. In general, clinicians should not routinely correct thrombocytopenia and coagulopathy before low risk therapeutic paracentesis, thoracentesis, and routine upper endoscopy for variceal ligation in patients with hepatic synthetic dysfunction induced coagulation abnormalities.
3. Blood products should be used sparingly because they increase portal pressure and carry a risk of Transfusion Associated Circulatory Overload (TACO), Transfusion Related Acute Lung Injury (TRALI), infection transmission, alloimmunization and/or transfusion reactions.
4. The following transfusion thresholds for management of active bleeding or high-risk procedures may optimize clot formation in advanced liver disease: hematocrit ≥25, platelet count >50,000, and Fibrinogen >120. Commonly utilized thresholds for INR correction are not supported by evidence.
5. Thrombopoietin (TPO) agonists are a good alternative to platelet transfusion but require time (about 10 days) to elevate platelet levels.
6. The large volume of fresh frozen plasma (FFP) required to reach an arbitrary INR target, limitations of the usual target, minimal effect on thrombin generation and adverse effects on portal pressure significantly limit the utility of this agent.
7. The 4-factor Prothrombin Complex Concentrate (PCC) contains both pro- and anticoagulant factors which offer an attractive low volume therapeutic to re-balance a disturbed hemostatic system. However, dosage is, in part, based on INR which is problematic in cirrhosis and published experience in liver disease is limited.
8. Anti-fibrinolytic therapy may be considered in patients with persistent bleeding from mucosal oozing or puncture wound bleeding consistent with impaired clot integrity. Both epsilon-aminocaproic acid and tranexamic acid inhibit clot dissolution. Neither is felt to generate a hypercoagulable state although both may exacerbate pre-existing thrombi.
9. Desmopressin (DDAVP) releases von Willebrand Factor (vWF) as its primary hemostatic mechanism. As this factor is usually elevated in cirrhosis, the agent lacks a sound evidence based foundation but may be useful in patients with concomitant renal failure.
10. Systemic heparin infusion is recommended for symptomatic DVT and PVT but there are unresolved issues regarding monitoring with both the anti-Xa assay and the partial thromboplastin time due to cirrhosis related antithrombin deficiency (heparin cofactor).
11. Treatment of incidental PVT depends upon estimated impact on transplant surgical complexity versus risks of bleeding and falls. Therapy with LMWH, vitamin K antagonists, and direct-acting anticoagulants (DOACs) improve PV repermeation versus observation alone.
12. DOACs such as the factor Xa and thrombin inhibitors are relatively safe and effective in stable cirrhotic patients but are in need of further study in patients with more advanced liver disease.
#Coagulation in #Cirrhosis
https://www.gastrojournal.org/article/S0016-5085(19)35694-X/pdf
Best Practice Advice
1. Global tests of clot formation such as rotational thromboelastometry (ROTEM), thromboelastography (TEG), Sonorheometry and Thrombin generation may eventually have a role in the evaluation of clotting in patients with cirrhosis but currently lack validated target levels.
2. In general, clinicians should not routinely correct thrombocytopenia and coagulopathy before low risk therapeutic paracentesis, thoracentesis, and routine upper endoscopy for variceal ligation in patients with hepatic synthetic dysfunction induced coagulation abnormalities.
3. Blood products should be used sparingly because they increase portal pressure and carry a risk of Transfusion Associated Circulatory Overload (TACO), Transfusion Related Acute Lung Injury (TRALI), infection transmission, alloimmunization and/or transfusion reactions.
4. The following transfusion thresholds for management of active bleeding or high-risk procedures may optimize clot formation in advanced liver disease: hematocrit ≥25, platelet count >50,000, and Fibrinogen >120. Commonly utilized thresholds for INR correction are not supported by evidence.
5. Thrombopoietin (TPO) agonists are a good alternative to platelet transfusion but require time (about 10 days) to elevate platelet levels.
6. The large volume of fresh frozen plasma (FFP) required to reach an arbitrary INR target, limitations of the usual target, minimal effect on thrombin generation and adverse effects on portal pressure significantly limit the utility of this agent.
7. The 4-factor Prothrombin Complex Concentrate (PCC) contains both pro- and anticoagulant factors which offer an attractive low volume therapeutic to re-balance a disturbed hemostatic system. However, dosage is, in part, based on INR which is problematic in cirrhosis and published experience in liver disease is limited.
8. Anti-fibrinolytic therapy may be considered in patients with persistent bleeding from mucosal oozing or puncture wound bleeding consistent with impaired clot integrity. Both epsilon-aminocaproic acid and tranexamic acid inhibit clot dissolution. Neither is felt to generate a hypercoagulable state although both may exacerbate pre-existing thrombi.
9. Desmopressin (DDAVP) releases von Willebrand Factor (vWF) as its primary hemostatic mechanism. As this factor is usually elevated in cirrhosis, the agent lacks a sound evidence based foundation but may be useful in patients with concomitant renal failure.
10. Systemic heparin infusion is recommended for symptomatic DVT and PVT but there are unresolved issues regarding monitoring with both the anti-Xa assay and the partial thromboplastin time due to cirrhosis related antithrombin deficiency (heparin cofactor).
11. Treatment of incidental PVT depends upon estimated impact on transplant surgical complexity versus risks of bleeding and falls. Therapy with LMWH, vitamin K antagonists, and direct-acting anticoagulants (DOACs) improve PV repermeation versus observation alone.
12. DOACs such as the factor Xa and thrombin inhibitors are relatively safe and effective in stable cirrhotic patients but are in need of further study in patients with more advanced liver disease.